{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:21:12Z","timestamp":1785766872555,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.012","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T07:54:59Z","timestamp":1691999699000},"page":"5525-5534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study"],"prefix":"10.1016","volume":"41","author":[{"given":"Kaoru","family":"Toyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-6007","authenticated-orcid":false,"given":"Tetsuo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Furihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1621-0929","authenticated-orcid":false,"given":"Yoshitaka","family":"Sogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kumazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Jonai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.07.012_b0005","unstructured":"Johns Hopkins University Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University; 2023. Available at https:\/\/coronavirus.jhu.edu\/map.html [accessed 1 May 2023]."},{"key":"10.1016\/j.vaccine.2023.07.012_b0010","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 \u2014 11 March 2020. Available at https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [accessed 1 May 2023]."},{"key":"10.1016\/j.vaccine.2023.07.012_b0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clinthera.2021.01.014","article-title":"The Covid-19 mRNA vaccines and the pandemic: Do they represent the beginning of the end or the end of the beginning?","volume":"43","author":"Jhaveri","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2023.07.012_b0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: Rapid development, implications, challenges and future prospects","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum Cell"},{"key":"10.1016\/j.vaccine.2023.07.012_b0025","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1126\/science.abm4915","article-title":"The changing epidemiology of SARS-CoV-2","volume":"375","author":"Koelle","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.07.012_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102792","article-title":"Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy","volume":"127","author":"Haque","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2023.07.012_b0035","first-page":"118","article-title":"Development of an mRNA vaccine against COVID-19","volume":"3","author":"Yabuta","year":"2021","journal-title":"Trans Regulat Sci"},{"key":"10.1016\/j.vaccine.2023.07.012_b0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: First approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2023.07.012_b0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.07.012_b0050","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration and Center for Biologics Evaluation and Research. Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials; 2007. Available at https:\/\/www.fda.gov\/media\/73679\/download [accessed 1 May 2023]."},{"key":"10.1016\/j.vaccine.2023.07.012_b0055","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Biologics Evaluation and Research. Development and licensure of vaccines to Prevent COVID-19: Guidance for industry; 2020. Available at https:\/\/www.fda.gov\/media\/139638\/download [accessed 1 May 2023]."},{"key":"10.1016\/j.vaccine.2023.07.012_b0060","unstructured":"Japan Ministry of Health, Labour and Welfare. Clinical management of patients with COVID-19 \u2014 version 2.1, 2020. Available at https:\/\/www.niph.go.jp\/h-crisis\/wp-content\/uploads\/2020\/07\/20200706103735_content_000646531.pdf [accessed 1 May 2023]."},{"key":"10.1016\/j.vaccine.2023.07.012_b0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.07.012_b0070","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.012_b0075","doi-asserted-by":"crossref","first-page":"e13083","DOI":"10.7717\/peerj.13083","article-title":"Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2","volume":"10","author":"Salleh","year":"2022","journal-title":"PeerJ"},{"key":"10.1016\/j.vaccine.2023.07.012_b0080","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa2117128","article-title":"Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina","volume":"386","author":"Lin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.012_b0085","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","article-title":"COVID-19 vaccine development: milestones, lessons and prospects","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2023.07.012_b0090","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/vaccines10040608","article-title":"COVID-19 vaccines: Current and future perspectives","volume":"10","author":"Soraci","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.07.012_b0095","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.012_b0100","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.07.012_b0105","doi-asserted-by":"crossref","first-page":"e64024","DOI":"10.1371\/journal.pone.0064024","article-title":"Human IgG subclasses against enterovirus type 71: Neutralization versus antibody dependent enhancement of infection","volume":"8","author":"Cao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.07.012_b0110","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/JVI.02155-10","article-title":"Human IgG subclasses: In vitro neutralization of and in vivo protection against West Nile virus","volume":"85","author":"Hofmeister","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.07.012_b0115","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1128\/JVI.75.14.6558-6565.2001","article-title":"Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1","volume":"75","author":"Scharf","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.07.012_b0120","doi-asserted-by":"crossref","first-page":"17642","DOI":"10.1038\/s41598-021-95045-z","article-title":"Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients","volume":"11","author":"Moura","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.07.012_b0125","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients","volume":"1","author":"Suthar","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2023.07.012_b0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12916-021-02055-9","article-title":"Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals","volume":"19","author":"Fraley","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.07.012_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737083","article-title":"The mrna-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity","volume":"12","author":"Tejedor Vaquero","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.07.012_b0140","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1038\/emi.2012.26","article-title":"Understanding the T cell immune response in SARS coronavirus infection","volume":"1","author":"Janice Oh","year":"2012","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.07.012_b0145","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.07.012_b0150","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3390\/v13101966","article-title":"Imbalanced immune response of T-cell and B-cell subsets in patients with moderate and severe COVID-19","volume":"13","author":"Golovkin","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.07.012_b0155","article-title":"Aging, immunity, and COVID-19: How age influences the host immune response to coronavirus infections?","volume":"11","author":"Bajaj","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.vaccine.2023.07.012_b0160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.07.012_b0165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"387","author":"Hachmann","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.012_b0170","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.07.012_b0175","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.07.012_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.671633","article-title":"Antibodies and vaccines target RBD of SARS-CoV-2","volume":"8","author":"Min","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.vaccine.2023.07.012_b0185","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2023.07.012_b0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2023.07.012_b0195","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41551-019-0399-y","article-title":"Imaging the early fate of mRNA vaccines","volume":"3","author":"Ols","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.vaccine.2023.07.012_b0200","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2023.07.012_b0205","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in Rhesus macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2023.07.012_b0210","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.vaccine.2023.07.012_b0215","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3390\/biomedicines10071538","article-title":"Vaccine mRNA can be detected in blood at 15 days post-vaccination","volume":"10","author":"Fertig","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.vaccine.2023.07.012_b0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41541-021-00393-6","article-title":"Scientific rationale for developing potent RBD-based vaccines targeting COVID-19","volume":"6","author":"Kleanthous","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.07.012_b0225","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/vaccines10122132","article-title":"Dynamics of antibody and T cell immunity against SARS-CoV-2 variants of concern and the impact of booster vaccinations in previously infected and infection-naive individuals","volume":"10","author":"Faas","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.07.012_b0230","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3390\/v14102086","article-title":"COVID-19 vaccines against omicron variant: Real-world data on effectiveness","volume":"14","author":"Kherabi","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.07.012_b0235","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.7150\/ijbs.73583","article-title":"Humoral and cellular immune responses of COVID-19 vaccines against SARS-CoV-2 omicron variant: A systemic review","volume":"18","author":"Chen","year":"2022","journal-title":"Int J Biol Sci"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:29:01Z","timestamp":1759404541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23008241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X23008241"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}